| __timestamp | Amgen Inc. | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 4699000000 | 5114000 |
| Thursday, January 1, 2015 | 4846000000 | 13403000 |
| Friday, January 1, 2016 | 5062000000 | 31056000 |
| Sunday, January 1, 2017 | 4870000000 | 35845000 |
| Monday, January 1, 2018 | 5332000000 | 48294000 |
| Tuesday, January 1, 2019 | 5150000000 | 63488000 |
| Wednesday, January 1, 2020 | 5730000000 | 88208000 |
| Friday, January 1, 2021 | 5368000000 | 102802000 |
| Saturday, January 1, 2022 | 5414000000 | 102464000 |
| Sunday, January 1, 2023 | 6179000000 | 76162000 |
| Monday, January 1, 2024 | 7096000000 | 72977000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of biotechnology, understanding the financial dynamics of industry giants like Amgen Inc. and emerging innovators like CRISPR Therapeutics AG is crucial. Over the past decade, from 2014 to 2023, Amgen's Selling, General, and Administrative (SG&A) expenses have consistently dwarfed those of CRISPR Therapeutics. Amgen's expenses peaked in 2023, reaching nearly 32% higher than their 2014 levels, reflecting its expansive operations and market reach.
Conversely, CRISPR Therapeutics, a pioneer in gene-editing technology, has seen its SG&A expenses grow exponentially, increasing by over 1,300% since 2014. This surge underscores its rapid growth and the increasing costs associated with scaling innovative biotech solutions. As these companies navigate the complexities of the biotech sector, their financial strategies offer a window into their operational priorities and market positioning.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Amgen Inc.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and CRISPR Therapeutics AG
Cost Management Insights: SG&A Expenses for Amgen Inc. and Vertex Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Amgen Inc. and Amneal Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and ImmunityBio, Inc.
Amgen Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Amgen Inc. and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing Madrigal Pharmaceuticals, Inc. and CRISPR Therapeutics AG
Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and CRISPR Therapeutics AG
Who Optimizes SG&A Costs Better? CRISPR Therapeutics AG or Geron Corporation